Obesity Medicine

Latest News

Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results

February 6th 2025

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction / image credit ©CLIPAREA_Custom Media/Shutterstock.com
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data

January 27th 2025

Novo Nordisk’s Amycretin Achieves Up to 22% Weight Loss in Phase 1b/2a Trial / Image credit: ©JHVE photo/AdobeStock
Novo Nordisk’s Amycretin Achieves Up to 22% Weight Loss in Phase 1b/2a Trial

January 24th 2025

GLP-1 Mimetic Benefits Are Broad, Study Finds, But Risks Can't be Ignored / image credit Courtesy of Washington University School of Medicine
GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored

January 21st 2025

Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity / image credit ©molekuule.be/stock.adobe.com
Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity

January 21st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.